Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response

Marco, Mirco Di; Veschi, Serena; Lanuti, Paola; Ramassone, Alice; Pacillo, Stefania; Pagotto, Sara; Pepe, Felice; George-William, Jonahunnatha Nesson; Curcio, Claudia; Marchisio, Marco; Miscia, Sebastianó; Innocenti, Idanna; Autore, Francesco; Vannata, Barbara; Gregorio, Patrizia Di; Gioacchino, Mario Di; Valentinuzzi, Silvia; Iezzi, Manuela; Mariani-Costantini, Renato; Larocca, Luigi Maria; Laurenti, Luca; Veronese, Angelo; Visone, Rosa

doi:10.3390/cancers13020257

Cited by 13 publications

(11 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The previous studies indicated that the miRNA-mediated effects depend on specific cell types and cellular context [23,24]. miR-181b was identified as regulating B cell differentiation and facilitating the maturation of cytotoxic T cells [25]. Indeed, miR-181b has been detected in many cancers, including breast cancer, pancreatic and gallbladder cancer, glioblastoma multiforme, and chronic lymphocytic leukemia [25][26][27][28][29].…”

Section: Discussionmentioning

confidence: 99%

“…miR-181b was identified as regulating B cell differentiation and facilitating the maturation of cytotoxic T cells [25]. Indeed, miR-181b has been detected in many cancers, including breast cancer, pancreatic and gallbladder cancer, glioblastoma multiforme, and chronic lymphocytic leukemia [25][26][27][28][29]. Moreover, several studies revealed that miR-181b could inhibit vascular inflammation and the initiation and progression of atherosclerosis [13,30].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

MicroRNA-181b Serves as a Circulating Biomarker and Regulates Inflammation in Heart Failure

et al. 2021

View full text Add to dashboard Cite

Heart failure (HF) is the typical terminal stage of cardiac diseases involving inflammatory states. The function of microRNAs (miRNAs) in the progress of HF remains poorly understood. In this study, real-time PCR results showed a decreased expression of miRNA-181b (miR-181b) in HF patients compared with healthy individuals. Besides, miR-181b expressions were negatively correlated with hypersensitive C-reactive protein (hsCRP) levels in the serum of HF patients. Receiver operator characteristic (ROC) curve analysis showed that miR-181b was a diagnostic predictor of HF, and the area under the curve was 0.970 (DCM-induced HF group) and 0.962 (ICM-induced HF group). Strikingly, in HF rats induced by isoproterenol (ISO), the expression of miR-181b of heart tissue was suppressed before tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) increase, as revealed by western blot and real-time PCR. Besides, the overexpression of miR-181b also decreased the expression of TNF-α, IL-1β, and IL-6 in lipopolysaccharide- (LPS-) induced neonatal cardiomyocytes. In conclusion, our results revealed that miR-181b might be a potential biomarker for HF and provided a novel target for anti-inflammatory therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

MicroRNA-181b Serves as a Circulating Biomarker and Regulates Inflammation in Heart Failure

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Other miRNAs involved in chemoresistance are miR-181a and miR-181b. Studies have evidenced that in aggressive CLL cases, the expression of miR-181b was decreased while conversely, the expression of this miRNA was constant in stable conditions of the disease [164,165]. In fact, miR-181b increased susceptibility to chemotherapy by targeting the 3'UTR region of the anti-apoptotic BCL-2 gene [166].…”

Section: Mirnas As Important Targets In Cll Treatmentmentioning

confidence: 99%

MicroRNAs: Potential prognostic and theranostic biomarkers in chronic lymphocytic leukemia

Ali,

Mahla,

Reza

et al. 2024

eJHaem

View full text Add to dashboard Cite

Small noncoding ribonucleic acids called microRNAs coordinate numerous critical physiological and biological processes such as cell division, proliferation, and death. These regulatory molecules interfere with the function of many genes by binding the 3'‐UTR region of target mRNAs to inhibit their translation or even degrade them. Given that a large proportion of miRNAs behave as either tumor suppressors or oncogenes, any genetic or epigenetic aberration changeing their structure and/or function could initiate tumor formation and development. An example of such cancers is chronic lymphocytic leukemia (CLL), the most prevalent adult leukemia in Western nations, which is caused by unregulated growth and buildup of defective cells in the peripheral blood and lymphoid organs. Genetic alterations at cellular and molecular levels play an important role in the occurrence and development of CLL. In this vein, it was noted that the development of this disease is noticeably affected by changes in the expression and function of miRNAs. Many studies on miRNAs have shown that these molecules are pivotal in the prognosis of different cancers, including CLL, and their epigenetic alterations (e.g., methylation) can predict disease progression and response to treatment. Furthermore, miRNAs are involved in the development of drug resistance in CLL, and targeting these molecules can be considered a new therapeutic approach for the treatment of this disease. MiRNA screening can offer important information on the etiology and development of CLL. Considering the importance of miRNAs in gene expression regulation, their application in the diagnosis, prognosis, and treatment of CLL is reviewed in this paper.

show abstract

“…Exosomes released in T-cell leukemia are implicated in the suppression of specific immune cells via the impairment of Treg and NK cell functions by miR-150 and miR-181 [180]. Overexpression of miR-181b in B-cells of chronic lymphocytic leukemia (CLL) resulted in an improved antitumor response of cytotoxic T-cells [181]. Overexpression of miR-195 in a human diffuse large B-cell lymphoma (DLBCL) cell line attenuated the immune escape of transformed cells by targeting PD-L1 [182].…”

Section: Hematological Malignanciesmentioning

confidence: 99%

Role of microRNAs in Immune Regulation with Translational and Clinical Applications

Gaál

2024

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are 19–23 nucleotide long, evolutionarily conserved noncoding RNA molecules that regulate gene expression at the post-transcriptional level. In this review, involvement of miRNAs is summarized in the differentiation and function of immune cells, in anti-infective immune responses, immunodeficiencies and autoimmune diseases. Roles of miRNAs in anticancer immunity and in the transplantation of solid organs and hematopoietic stem cells are also discussed. Major focus is put on the translational clinical applications of miRNAs, including the establishment of noninvasive biomarkers for differential diagnosis and prediction of prognosis. Patient selection and response prediction to biological therapy is one of the most promising fields of application. Replacement or inhibition of miRNAs has enormous therapeutic potential, with constantly expanding possibilities. Although important challenges still await solutions, evaluation of miRNA fingerprints may contribute to an increasingly personalized management of immune dysregulation with a remarkable reduction in toxicity and treatment side effects. More detailed knowledge of the molecular effects of physical exercise and nutrition on the immune system may facilitate self-tailored lifestyle recommendations and advances in prevention.

show abstract

Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response

Cited by 13 publications

References 49 publications

MicroRNA-181b Serves as a Circulating Biomarker and Regulates Inflammation in Heart Failure

MicroRNA-181b Serves as a Circulating Biomarker and Regulates Inflammation in Heart Failure

MicroRNAs: Potential prognostic and theranostic biomarkers in chronic lymphocytic leukemia

Role of microRNAs in Immune Regulation with Translational and Clinical Applications

Contact Info

Product

Resources

About